The association between toxicity and efficacy of immune checkpoint inhibitors in older adults with NSCLC.

IF 2.7 4区医学 Q3 IMMUNOLOGY

Immunotherapy Pub Date : 2024-09-13 DOI:10.1080/1750743x.2024.2394382

Yiran Rong,Sujith Ramachandran,Kaustuv Bhattacharya,Yi Yang,Sally Earl,Yunhee Chang,John P Bentley

引用次数: 0

Abstract

Aim: This cohort study evaluated the association between immune checkpoint inhibitors (ICIs)-induced immune-related adverse events (irAEs) and mortality as well as ICI discontinuation among older adults with NSCLC.Methods: 2007-2019 Surveillance, Epidemiology and End Results-Medicare linked database was used and survival analysis with time-varying exposure of irAEs was applied to estimate the associations.Results & conclusion: A total of 8,175 individuals were included, with 46.8% of whom developed an irAE. Cox regression models showed the occurrence of any irAEs was associated with increased risk of mortality (HR: 1.73, 95% CI: 1.63-1.82) and treatment discontinuation (HR: 1.87, 95% CI: 1.78-1.97). Some variability was observed in the effect on the two outcomes depending on the type of irAE.

查看原文本刊更多论文

免疫检查点抑制剂对 NSCLC 老年患者的毒性与疗效之间的关联。

目的：这项队列研究评估了免疫检查点抑制剂（ICIs）诱发的免疫相关不良事件（irAEs）与NSCLC老年患者的死亡率和ICI停药之间的关联。方法：使用2007-2019年监测、流行病学和最终结果--医保链接数据库，并应用irAEs暴露随时间变化的生存分析来估计关联。结果与结论：共纳入8175人，其中46.8%的人发生了irAE：共纳入了8175人，其中46.8%的人发生了虹膜AE。Cox回归模型显示，任何irAEs的发生都与死亡率（HR：1.73，95% CI：1.63-1.82）和中断治疗（HR：1.87，95% CI：1.78-1.97）风险的增加有关。根据虹膜睫状体异常的类型，对这两种结果的影响存在一定的差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.